ClinicalTrials.gg
CompletedNCT06703203Updated Mar 30, 2026

Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine

A Phase 1/2 interventional study of 26-Valent pneumococcal conjugate vaccine and 23-Valent pneumococcal polysaccharide vaccine in Pneumococcal Vaccines, sponsored by Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. Completed at 1 site in China. Open to participants aged 2 Months and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (part of Chongqing Zhifei Biological Products Co., Ltd.) · Phase 1/2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
2 Months and older
Sex
All
01

Study summary

The purpose of this experiment is to evaluate the safety and immunogenicity of the 26 valent pneumococcal conjugate vaccine in the population aged 2 months and above.

Read the detailed description

A single-center, randomized, double-blind, active-controlled trial design (Phase I/II) was used. In addition, according to the requirements in the approval letter of this product (2024LP01053), serum standards need to be established for the newly added types (24F, 35B). Therefore, a calibration group is set and an open study design is adopted.

02

Conditions studied

  • Pneumococcal Vaccines

Keywords

  • 26 valent pneumococcal conjugate vaccine
03

In context

Lead sponsor

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd is the lead sponsor of 22 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Months and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject is 2-3 months old (minimum 6 weeks old), 7 months old and above at the time of enrollment, and the legal guardian and/or the subject can provide legal identification certificate;
  • The subjects themselves and/or their legal guardians understand the vaccination and trial procedures, voluntarily participate in the trial and sign the form;
  • The subject and/or legal guardian can comply with the clinical trial protocol, have the ability to use thermometer, scale and fill in diary card and contact card as required;
  • Female subjects of agree to take effective measures from enrollment to 6 months after vaccination.
  • For calibration group subjects: 18 to 55 years of age, ≥ 50 kg for males or ≥ 45 kg for females.

Exclusion criteria

Exclusion Criteria:

  • Axillary body temperature ≥ 37.3 ℃ on the day of enrollment;
  • History of infectious diseases caused by Streptococcus pneumoniae confirmed by bacterial culture within 3 years;
  • Have received or plan to receive a Streptococcus pneumoniae vaccine outside the trial protocol, including marketed or other Streptococcus pneumoniae vaccines;
  • Pregnant or lactating women; Previous history of severe allergy to any vaccine or drug, such as urticaria, dyspnea, angioneurotic edema, anaphylactic shock, Henoch-Schonlein purpura, thrombocytopenic purpura;
  • Allergic to any component of the investigational vaccine;
  • Suffering from severe respiratory diseases (such as severe asthma), heart diseases, liver diseases, kidney diseases, congenital malformations, developmental disorders and genetic defects (including but not limited to: down syndrome, thalassemia major, etc.) that may interfere with the conduct or completion of the trial;
  • Diagnosed with congenital or acquired immunodeficiency, or suspected to have serious chronic disease or systemic disease that may interfere with the conduct or completion of the trial, such as: active tuberculosis, (HIV) infection, etc.;
  • Encephalopathy, uncontrolled epilepsy, convulsion and other progressive neurological diseases, or a history or family history of mental illness;
  • for intramuscular injection such as thrombocytopenia, any coagulation disorder or receiving anticoagulant therapy;
  • Asplenia or splenectomy, functional asplenia due to any condition;
  • therapy, cytotoxic therapy or therapy within 3 months prior to vaccination, such as systemic glucocorticoid therapy for more than 2 consecutive weeks, such as prednisone or similar drugs > 5 mg/day (excluding corticosteroid spray therapy for allergic rhinitis, surface corticosteroid therapy for acute non-complicated dermatitis);
  • Received blood products or immunoglobulins within 3 months prior to enrollment ( immunoglobulin is acceptable), or planned to be used during the trial (before the last immunogenicity blood sample collection);
  • Within 3 days before the first dose of vaccine, the patient has acute illness or is in acute attack of chronic disease, or has used antipyretic, analgesic or anti-allergic drugs (such as: acetaminophen, ibuprofen, aspirin, etc.);
  • Received non- within 7 days (≤ 7 days) or live attenuated vaccine within 14 days (≤ 14 days) prior to enrollment;
  • Hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg, applicable to adults);
  • Abnormal and laboratory test results, which are not suitable for enrollment as determined by the investigator (applicable to subjects aged 2 years and older in Phase I);
  • Birth weight \< 2.5 kg, premature delivery (gestational age \< 37 weeks), history of abnormal labor process, history of asphyxia rescue, history of nerve organ damage, history of pathological jaundice confirmed by diagnosis;
  • For Standardised Subjects:

    ① (ALT) or aspartate aminotransferase (AST) ≥ 50 U/L; Or ≤ 115 g/L (female)/120g/L (male); Any positive serology for hepatitis B, , HIV, or syphilis.

  • Plans to move before the end of the trial or leave the area for an extended period of time during scheduled trial visits;
  • Ongoing participation or planning to participate in other clinical trials (vaccines, drugs, medical devices, etc.) in the near future;
  • Subject has any condition that, in the opinion of the investigator, may interfere with the evaluation of the objectives of the trial.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
450 participants (actual)

Study arms

  • Other
    ≥60 years old age group (for phase Ⅰ)

    There are 30 subjects in ≥60 years old age group, randomly assigned to the experimental group and the control group in a 2:1 ratio.

    Biological: 26-Valent pneumococcal conjugate vaccine · Biological: 23-Valent pneumococcal polysaccharide vaccine

  • Other
    18-59 years old age group (for phase Ⅰ)

    There are total 40 subjects in 18-59 age group. Among them, 30 subjects were randomly assigned to the experimental group and the control group in a 2:1 ratio. In addition, other 10 subjects aged 18-55 to receive the experimental vaccine as the serum calibration test population.

    Biological: 26-Valent pneumococcal conjugate vaccine · Biological: 23-Valent pneumococcal polysaccharide vaccine

  • Other
    6-17 years old age group (for phase Ⅰ)

    There are 30 subjects in 6-17 years old age group, randomly assigned to the experimental group and the control group in a 2:1 ratio.

    Biological: 26-Valent pneumococcal conjugate vaccine · Biological: 23-Valent pneumococcal polysaccharide vaccine

  • Other
    2-5 years old age group (for phase Ⅰ/Ⅱ)

    There are total 230 people in 2-5 years old age group. Among them, there were 30 subjects included in the phase Ⅰ clinical trial and were randomly assigned to the experimental group and the control group in a 2:1 ratio. And the other 200 people were included for phase Ⅱ and were randomly assigned to the experimental group and the control group in a 1:1 ratio.

    Biological: 26-Valent pneumococcal conjugate vaccine · Biological: 13-Valent pneumococcal conjugate vaccine

  • Other
    13-23 months old age group (for phase Ⅰ)

    There are 30 subjects in 13-23 months old age group, randomly assigned to the experimental group and the control group in a 2:1 ratio.

    Biological: 26-Valent pneumococcal conjugate vaccine · Biological: 13-Valent pneumococcal conjugate vaccine

  • Other
    7-11 months old age group (for phase Ⅰ)

    There are 30 subjects in 7-11 months old age group, randomly assigned to the experimental group and the control group in a 2:1 ratio.

    Biological: 26-Valent pneumococcal conjugate vaccine · Biological: 13-Valent pneumococcal conjugate vaccine

  • Other
    3 months old age group (for phase Ⅰ)

    There are 30 subjects in 3 months old age group, randomly assigned to the experimental group and the control group in a 2:1 ratio.

    Biological: 26-Valent pneumococcal conjugate vaccine · Biological: 13-Valent pneumococcal conjugate vaccine

  • Other
    2 months old age group (for phase Ⅰ)

    There are 30 subjects in 2 months old age group, randomly assigned to the experimental group and the control group in a 2:1 ratio.

    Biological: 26-Valent pneumococcal conjugate vaccine · Biological: 13-Valent pneumococcal conjugate vaccine

Interventions

  • Biological26-Valent pneumococcal conjugate vaccine

    As an experimental group. The active ingredient of 26-valent pneumococcal conjugate vaccine is the capsular polysaccharide of 26 pneumococcal serotypes conjugated to the tetanus toxoid carrier protein. Administer one dose of 0.5mL each time.

  • Biological23-valent pneumococcal capsular polysaccharide vaccineStudies of 23-valent pneumococcal capsular polysaccharide vaccine23-valent pneumococcal capsular polysaccharide vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    As a control group. The effective ingredients of 23-valent pneumococcal polysaccharide vaccine are 23 serotypes of pneumococcal capsular polysaccharides. Administer one dose of 0.5mL each time.

  • Biological13-valent pneumococcal vaccineStudies of 13-valent pneumococcal vaccine13-valent pneumococcal vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    As a control group. The active ingredient of 13-valent pneumococcal conjugate vaccine is the capsular polysaccharide of 13 pneumococcal serotypes conjugated to the tetanus toxoid carrier protein. Administer one dose of 0.5mL each time.

06

What researchers measure

Primary outcomes

  1. AE occurrences within 0-30 days after each dose of vaccination (for phase Ⅰ/Ⅱ)

    All AE occurrences within 0-30 days after each dose of vaccination (number of cases, incidence rate, and relationship with vaccination)

    Time frame: 30 day after each vaccination

  2. Solicited AE occurrences within 0-30 minutes after each dose of vaccination (for phase Ⅰ/Ⅱ)

    The occurrence of Solicited adverse events (AE) within 0-30 minutes after each dose of vaccination (number of cases, incidence rate, and relationship with vaccination)

    Time frame: 30 minutes after each vaccination

  3. Solicited AE occurrences within 0-7 days after each dose of vaccination (for phase Ⅰ/Ⅱ)

    The occurrence of solicited adverse events (AE) within 0-7 days after each dose of vaccination (number of cases, incidence rate, and relationship with vaccination);

    Time frame: 0-7 days after each vaccination

  4. Unsolicited AE occurrences within 0-30 days after each dose of vaccination (for phase Ⅰ/Ⅱ)

    The occurrence of unsolicited adverse events (AE) within 0-30 days after each dose of vaccination (number of cases, incidence rate, and relationship with vaccination);

    Time frame: 0-30 days after each vaccination

  5. Grade 3 and above AE occurrences within 0-30 days after each dose of vaccination (for phase Ⅰ/Ⅱ)

    The occurrence of grade 3 and above adverse events within 0-30 days after each dose of vaccination (number of cases, incidence rate, and relationship with vaccination).

    Time frame: 0-30 days after each vaccination

  6. All SAE occurrences within 0-6 months after vaccination (for Phase Ⅱ)

    The occurrence of all serious adverse reactions within 6 months after vaccination (number of cases, incidence rate, and relationship with vaccination)

    Time frame: 0-6 months after each vaccination

  7. Positive rate of serotype-specific pneumococcal IgG antibody on the 30th day after immunization in subjects aged 2-5 years (for phase Ⅱ)

    Proportion of subjects with serotype-specific pneumococcal IgG antibody concentration ≥ 0.35 μg/ml on Day 30 after vaccination in subjects aged 2-5 years

    Time frame: 30 day after vaccination

Secondary outcomes

  1. All SAE in the population aged ≥12 months during 0-6 months after vaccination (for phase Ⅰ)

    All SAE in the population aged 12 months and older from the first dose to 6 months after the full course of vaccination

    Time frame: 0-6 months after vaccination

  2. All SAE in the population aged <12 months from the first dose to 6 months after the primary immunization and from the booster to 6 months after the booster(for phase Ⅰ)

    All SAE from the first dose to 6 months after the primary immunization and from the booster to 6 months after the booster in the population less than 12 months of age.

    Time frame: From the first dose to 6 months after the primary immunization and from the booster to 6 months after the booster

  3. Proportion of IgG antibodies ≥ 1.0 µg/mL and GMC results on Day 30 post-immunization(for phase Ⅱ)

    Proportion of subjects with serotype-specific pneumococcal IgG antibodies ≥ 1.0 µg/mL and GMC results on Day 30 post-immunization in subjects 2 to 5 years of age.

    Time frame: 30 day after vaccination

07

Study locations

1 site
  • Henan Provincial Center for Disease Control and Prevention
    Shangqiu, Henan 476700, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in Aug 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2024
First posted
Nov 25, 2024
StartActual
Jul 17, 2025
Primary completionActual
Aug 5, 2025
CompletionActual
Feb 5, 2026
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06703203
Responsible party
Sponsor
First posted
Nov 25, 2024
Start date
Jul 17, 2025
Primary completion
Aug 5, 2025
Completion
Feb 5, 2026
Last update
Mar 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion